Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579693 · ClinicalTrials.gov registry record · Phase 2
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03579693 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 26 participants.
The verdict
NCT03579693, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Chronic kidney disease is associated with the loss of skeletal muscle mass and function. This process detrimentally impacts mobility, functional independence, and quality of life. Mounting evidence suggests that chronic kidney disease impairs skeletal muscle functioning by injuring mitochondria, the central energy producing units of cells. Potential treatment options to restore mitochondrial function include aerobic and weight bearing exercise and medications that directly improve mitochondrial energetics. Unfortunately, exercise programs may be difficult to implement in people who have chronic diseases, such as kidney disease.. Coenzyme Q10 (coQ10) and nicotinamide riboside (NR) are naturally occurring supplements that can directly improve mitochondrial efficiency. Both compounds help mitochondria produce more energy while generating less waste. The primary purpose of this study is to test whether coQ10 and NR can improve muscle function among people with chronic kidney disease. What we learn in this study may help us better understand the mechanisms of skeletal muscle impairment among people with kidney disease and ultimately improve their ability to be active and independent.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT CoQ10
- DIETARY_SUPPLEMENT Nicotinamide riboside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579693
The ClinicalTrials.gov registry entry for NCT03579693 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03579693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579693 about?
NCT03579693 is a clinical study titled "Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease". Chronic kidney disease is associated with the loss of skeletal muscle mass and function. This process detrimentally impacts mobility, functional independence, and quality of life. Mounting evidence suggests that chronic kidney disease impairs skeletal muscle functioning by injuring mitochondria, the...
What is the current status of trial NCT03579693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2018-11-14. Estimated completion is 2021-04-26.
What interventions are being tested in trial NCT03579693?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), CoQ10 (DIETARY_SUPPLEMENT), Nicotinamide riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03579693?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.